Background Most people who receive a kidney transplant die from either cardiovascular
disease or cancer before their transplant fails. The most common reason for someone with a …

New immunosuppressants and the better use of immunosuppressant combination therapy
have led to significant improvements in renal allograft outcomes over the last decades. Yet …

Background In previous analyses of BENEFIT, a phase 3 study, belatacept-based
immunosuppression, as compared with cyclosporine-based immunosuppression, was …

In the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line
Immunosuppression Trial–Extended Criteria Donors (BENEFIT-EXT), extended criteria …

Donor‐specific antibodies (DSA s) are associated with an increased risk of antibody‐
mediated rejection and graft failure. In BENEFIT and BENEFIT‐EXT, kidney‐transplant …

Tacrolimus, a calcineurin inhibitor, has been the cornerstone of immunosuppressive
regimens in renal transplant over 2 decades. This has significantly improved the outcomes …

Demographic changes are associated with a steady increase of older patients with end-
stage organ failure in need for transplantation. As a result, the majority of transplant …

The old-for-old allocation policy used for kidney transplantation (KT) has confirmed the
survival benefit compared to remaining listed on dialysis. Shortage of standard donors has …

BACKGROUND: End-stage renal disease is a long-term irreversible decline in kidney
function requiring renal replacement therapy: kidney transplantation, haemodialysis or …

In kidney transplant recipients with chronic graft dysfunction, long‐term immunosuppression
with calcineurin inhibitors (CNI s) or mTOR inhibitors (mTOR i) can be challenging due to …